Evidence map›Paper›PMID 30736355›Full record

ReviewCancers2019

Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies.

Benjamin Heyman, Yiping Yang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Benjamin HeymanDivision of Regenerative Medicine, Department of Medicine, UC San Diego, La Jolla, CA 92093, USA. bheyman@ucsd.edu.
Yiping YangDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Department of Immunology, Duke University, Durham, NC 27710, USA. yang0029@mc.duke.edu.
Duke University · USUniversity of California, San Diego · US

Funding

Novel Strategies for Cancer Immunotherapy in Stem Cell TransplantR01CA136934 · NCI · OHIO STATE UNIVERSITY · PI YANG, YIPING · 2009 to 2018
$3.4M
T Memory Stem Cells in CancerR01CA193167 · NCI · OHIO STATE UNIVERSITY · PI YANG, YIPING · 2016 to 2020
$2.2M
NCI NIH HHS R01 CA136934NCI NIH HHS R01 CA193167NIH HHS R01-CA136934NIH HHS R01-CA193167
6 · The paper itself

Abstract

Chimeric antigen receptor T cells (CAR T Cells) have led to dramatic improvements in the survival of cancer patients, most notably those with hematologic malignancies. Early phase clinical trials in patients with solid tumors have demonstrated them to be feasible, but unfortunately has yielded limited efficacy for various cancer types. In this article we will review the background on CAR T cells for the treatment of solid tumors, focusing on the unique obstacles that solid tumors present for the development of adoptive T cell therapy, and the novel approaches currently under development to overcome these hurdles.

Indexed as

CAR T cellsnovel approachessolid tumors

Identifiers

PMID30736355
PMCPMC6407020
OpenAlexW2914726601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.